SAS Output

14-AUG-2026 6:11

Lung-MAP ACCRUAL REPORT


	O P E N	ACCR GOAL	TOTAL REGS.	REGS. LAST 12 Month	REGS. LAST 6 Month	REGS. LAST 3 Month	REGS. LAST 30 DAYS	REGS. LAST 7 DAYS	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs
LUNGMAP Screening Protocol Registrations
Total			4081	378	180	85	28	4	02/06/2019	474	184
Screened at PD			1544	245	129	57	18	4
Pre-Screened prior to PD			2511	116	45	23	8	0
Treatment-naive			26	17	6	5	2	0
ctDNA Specimen Submission			315	0	0	0	0	0
Re-analysis Requests			537	29	13	4	2	1

Sub-Study Assignments
LUNGMAP Sub-Study Assignments			2247	307	158	73	22	6
Screened at PD			1314	246	132	60	19	5
Pre-Screened prior to PD			849	41	18	7	1	1
Treatment-naive			26	17	6	5	2	0
After PD on a Lung_MAP Sub-Study			58	3	2	1	0	0

Sub-Study Assignments (open studies only)
S1800E			433	266	139	60	19	6
S1900G			41	10	7	6	0	0
S1900J			18	6	3	0	0	0
S1900K			44	24	8	6	2	0
S1900N			1	1	1	1	1	0

Sub-Study Registrations
LUNGMAP Sub-Study Registrations			664	144	77	43	15	3
Initial sub-study registrations			651	143	76	42	15	3
Subsequent sub-study registrations			13	1	1	1	0	0

Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab		378	129	118	67	36	14	3	05/22/2025	358	118
Docetaxel plus Ramucirumab	Y		67	61	36	18	8	2
Cemiplimab plus Docetaxel and Ramucirumab	Y		62	57	31	18	6	1
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu		44	28	7	4	3	1	0	05/05/2023	336	107
Capmatinib + Osimertinib + Ramucirumab	Y		16	5	2	2	1	0
Capmatinib + Osimertinib	Y		12	2	2	1	0	0
S1900J: MET Amplification: Amivantamab Hyaluronidase		88	4	2	1	0	0	0	11/19/2024	280	86
Amivantamab Hyaluronidase	Y		4	2	1	0	0	0
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab		56	29	17	5	4	0	0	08/08/2024	273	90
Tepotinib + Ramucirumab	Y		20	12	4	4	0	0
Tepotinib	Y		9	5	1	0	0	0